The global veterinary diagnostics market was valued at USD 9.29 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 10.02% from 2024 to 2030. Several factors are driving this growth, including increased spending on animal healthcare, a rising incidence of diseases in animals, advancements in diagnostic technologies, and a higher rate of medicalization in veterinary care. For example, in November 2023, IDEXX launched the SNAP Leish 4Dx Test in Europe and Asia, aimed at screening for vector-borne diseases like canine leishmaniosis. This launch expanded the company's diagnostic portfolio, reflecting how continuous innovations are bolstering the market.

The ongoing advancements in veterinary diagnostic technologies, such as molecular diagnostics, imaging modalities, and point-of-care (PoC) testing, have substantially enhanced the ability to diagnose a wide range of animal diseases. These technologies not only improve the accuracy and speed of diagnostic processes but also contribute to the overall market growth, as veterinarians and pet owners increasingly seek cutting-edge solutions for comprehensive animal healthcare.

One of the key growth drivers in the market is the development and adoption of PoC diagnostic tools, which provide rapid, on-site results. These tools are essential for quick decision-making in veterinary practices, enabling more timely and effective treatments. This is particularly important for improving health outcomes for animals, as early and efficient treatment often leads to better prognoses.

The rising prevalence of infectious diseases among animals, including zoonotic diseases (diseases that can be transmitted from animals to humans), has also emphasized the need for accurate and timely diagnostics. As a result, veterinarians are increasingly relying on advanced diagnostic tools to manage these diseases effectively, further driving the demand for veterinary diagnostics.

Gather more insights about the market drivers, restrains and growth of the Veterinary Diagnostics Market

Testing Category Insights Segment

In 2023, the clinical chemistry segment emerged as the leader in the veterinary diagnostics market, commanding a significant share of 23.44%. This segment includes tests designed to analyze the chemical composition of various biological samples, such as blood or urine, to evaluate an animal’s organ function. These tests play a crucial role in diagnosing a range of health conditions, including pancreatitis, diabetes, and liver or kidney diseases, offering veterinarians valuable insights into an animal's internal health status. Additionally, clinical chemistry tests are frequently used to monitor how well animals are responding to specific treatments, ensuring that therapy can be adjusted as needed for optimal outcomes. The wide availability and high adoption of these tests across veterinary practices contribute significantly to the segment's dominance within the market. As these tests are relatively routine in veterinary care, their accessibility and ability to provide quick, actionable results make them indispensable in diagnosing and managing animal health.

Looking forward, the cytopathology segment is projected to experience the fastest growth, with an anticipated compound annual growth rate (CAGR) of 13.95% from 2024 to 2030. Cytopathology involves the detailed examination of cells obtained from body fluids or tissues, offering a minimally invasive way to diagnose various diseases, including cancers, infections, and inflammatory conditions. The rising importance of early disease detection, particularly for conditions such as cancer, is driving the demand for cytopathology in veterinary diagnostics.

An excellent example of innovation in this segment came in January 2020, when IDEXX Laboratories launched digital cytology services. These services are powered by the company’s proprietary VetConnect PLUS software and supported by an in-clinic instrument that allows veterinarians to digitally share cytology samples with a global network of over 100 veterinary pathologists. Veterinarians can receive expert cytology interpretations within just two hours, dramatically speeding up the diagnostic process. Such innovations not only improve the accuracy and speed of diagnoses but also enhance overall animal care by enabling faster treatment decisions. The success of initiatives like these, combined with continued advancements in cytology technology, is expected to drive the rapid growth of the cytopathology segment over the forecast period.

Moreover, the growing awareness among veterinarians and pet owners about the benefits of cellular-level analysis in diagnosing complex conditions further supports this segment's rise. As diagnostic capabilities continue to expand, the cytopathology segment is likely to play a pivotal role in improving early detection and treatment of diseases in animals.

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.